The Department of Health and Human Services (HHS), announced that HHS and Pfizer have reached an agreement that extends patient access to Paxlovid, maximizes taxpayer investment, and begins Paxlovid’s transition to the commercial market in November 2023. This agreement builds on HHS and Pfizer’s strong partnership over the last three years that enabled the development, manufacture, and distribution of COVID-19 vaccines and therapeutics at a record pace. Paxlovid is a prescription medicine used to treat COVID‑19 in adults who are at high risk for progression to severe illness, including hospitalization or death.
Zachary Mackenzie
Xavier Graduate
PPP and Political Science Major
Community Building Institute
248-639-0103